Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1997017088) MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/017088 International Application No.: PCT/GB1996/002746
Publication Date: 15.05.1997 International Filing Date: 08.11.1996
Chapter 2 Demand Filed: 20.05.1997
IPC:
A61K 38/55 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55
Protease inhibitors
Applicants:
CHIROSCIENCE LIMITED [GB/GB]; Cambridge Science Park Milton Road Cambridge CB4 4WE, GB (AllExceptUS)
POPE, Nicholas, Robert [GB/GB]; GB (UsOnly)
WILLS, Ruth, Elizabeth [GB/GB]; GB (UsOnly)
Inventors:
POPE, Nicholas, Robert; GB
WILLS, Ruth, Elizabeth; GB
Agent:
GILL JENNINGS & EVERY; Broadgate House 7 Eldon Street London EC2M 7LH, GB
Priority Data:
9523066.010.11.1995GB
Title (EN) MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USE
(FR) INHIBITEURS DE METALLOPROTEINASE MATRICIELLE ET LEUR UTILISATION THERAPEUTIQUE
Abstract:
(EN) A matrix metalloproteinase inhibitor is used for the treatment of a subject of a subject susceptible to or exhibiting a condition that can be treated with the inhibitor, wherein the treatment is conducted after surgical operation on the subject, and wherein the inhibitor exhibits an IC50 of below 100 $g(m)M with respect to matrix metalloproteinase and causes no or a partial reduction in levels of tumour necrosis factor.
(FR) On utilise un inhibiteur de métalloprotéinase matricielle dans le traitement d'un sujet sensible à un état pouvant être traité à l'aide de cet inhibiteur, ou présentant un tel état. On conduit ce traitement après une opération chirurgicale pratiquée sur ce sujet et l'inhibiteur, d'une part, démontre un IC50 inférieur à 100 $g(m)M par rapport à la métalloprotéinase matricielle et, d'autre part, ne provoque pas de diminution des concentrations du facteur de nécrose tumorale ou provoque une diminution partielle de celles-ci.
Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU1996075026